ADMA Biologics Inc (NASDAQ:ADMA) Receives Consensus Rating of "Hold" from Analysts

Key Points

• Analysts give ADMA Biologics a consensus rating of Hold (three holds, two buys) with a 12‑month average price target of $19, and several firms have trimmed targets (e.g., Mizuho to $20, Canaccord to $18).
• Q1 results showed EPS of $0.19 in line with estimates but revenue missed at $114.5M versus roughly $140M expected, and management cut FY‑2026 revenue guidance to $530–$560M and withdrew longer‑term guidance—moves that drove the share decline and multiple securities‑fraud probes.
• Offsetting risks, ADMA won an FDA label expansion for ASCENIV and reported strong margins and cash flow with ASCENIV revenue up ~28% YoY, supporting the product growth story despite market/channel scrutiny.

Shares of ADMA Biologics Inc (NASDAQ:ADMA - Get Free Report) have been given an average recommendation of "Hold" by the five brokerages that are currently covering the stock, Marketbeat reports. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $19.00.

ADMA has been the subject of several recent research reports. Mizuho decreased their price target on shares of ADMA Biologics from $24.00 to $20.00 and set an "outperform" rating for the company in a research report on Thursday. Cantor Fitzgerald reissued a "neutral" rating on shares of ADMA Biologics in a research note on Thursday, March 26th. Zacks Research downgraded ADMA Biologics from a "strong-buy" rating to a "hold" rating in a report on Monday, April 27th. Wall Street Zen downgraded ADMA Biologics from a "buy" rating to a "hold" rating in a report on Monday. Finally, Canaccord Genuity Group reduced their price target on ADMA Biologics from $21.00 to $18.00 and set a "buy" rating on the stock in a research report on Thursday.

ADMA Biologics Stock Performance

NASDAQ:ADMA opened at $8.47 on Friday. The stock's 50-day moving average is $12.12 and its 200-day moving average is $15.47. ADMA Biologics has a 1-year low of $7.21 and a 1-year high of $22.73. The company has a current ratio of 6.71, a quick ratio of 3.74 and a debt-to-equity ratio of 0.16. The stock has a market cap of $2.02 billion, a P/E ratio of 12.46 and a beta of 0.83.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.19. ADMA Biologics had a net margin of 32.43% and a return on equity of 38.94%. The business had revenue of $114.49 million during the quarter, compared to analyst estimates of $139.98 million. During the same quarter last year, the business earned $0.11 EPS. The firm's quarterly revenue was down .3% on a year-over-year basis. Equities research analysts anticipate that ADMA Biologics will post 0.93 earnings per share for the current year.

Key Headlines Impacting ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: Company reported strong profitability, cash flow and ASCENIV momentum — Q1 adjusted net income and adjusted EBITDA grew year‑over‑year, cash from operations was strong, and ASCENIV revenue rose ~28% YoY, supporting margin durability. ADMA Biologics Reports Q1 Results
• Positive Sentiment: Regulatory win: expanded ASCENIV label approval from FDA should support commercial uptake and reinforces the product growth story. FDA Expanded ASCENIV Label
• Neutral Sentiment: Earnings details mixed: EPS of $0.19 met consensus (Y/Y improvement), but revenues of $114.5M missed analyst estimates, signaling near‑term topline pressure even as per‑unit margins remain strong. Zacks Q1 Coverage
• Neutral Sentiment: Analyst adjustments: Mizuho trimmed its price target (from $24 to $20) but retained an outperform stance, reflecting continued conviction in long‑term upside despite near‑term headwinds. Benzinga Note on Mizuho
• Negative Sentiment: Company cut FY‑2026 revenue guidance to $530M–$560M (consensus had been ~$625M) and withdrew longer‑term guidance, citing evolving U.S. plasma/IG market dynamics — the guidance cut is the primary driver of the share decline. Seeking Alpha on Guidance Cut
• Negative Sentiment: Market scrutiny and investigations: multiple law firms have launched securities‑fraud probes (Pomerantz, Kehoe, Block & Leviton, Rosen, BFA), increasing legal and reputational risk and likely amplifying sell pressure. Pomerantz Investigation Kehoe Firm Notice
• Negative Sentiment: Channel scrutiny / short‑seller aftermath: media and analysts flagged potential channel stuffing and competitive pressures in the IG market; these narratives likely intensified the sell‑off and elevated volatility. Investing.com on Channel Scrutiny

Insider Buying and Selling

In related news, Director Steve Elms acquired 7,000 shares of the business's stock in a transaction that occurred on Thursday, March 5th. The shares were bought at an average cost of $15.67 per share, with a total value of $109,690.00. Following the completion of the purchase, the director directly owned 2,038,730 shares in the company, valued at $31,946,899.10. The trade was a 0.34% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $15.63, for a total transaction of $157,800.48. Following the sale, the chief operating officer directly owned 466,600 shares of the company's stock, valued at $7,292,958. This represents a 2.12% decrease in their position. The SEC filing for this sale provides additional information. 3.90% of the stock is owned by insiders.

Hedge Funds Weigh In On ADMA Biologics

A number of hedge funds have recently bought and sold shares of the company. Summit Securities Group LLC bought a new stake in ADMA Biologics during the fourth quarter valued at $29,000. Rothschild Investment LLC raised its position in shares of ADMA Biologics by 373.8% in the 3rd quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 1,495 shares in the last quarter. Optima Capital LLC acquired a new position in shares of ADMA Biologics in the 4th quarter valued at about $36,000. Clearstead Advisors LLC lifted its stake in shares of ADMA Biologics by 55.7% in the 3rd quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company's stock valued at $33,000 after purchasing an additional 795 shares during the period. Finally, iSAM Funds UK Ltd bought a new stake in shares of ADMA Biologics during the 3rd quarter valued at about $34,000. Institutional investors own 75.68% of the company's stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company's marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.